Oppenheimer analyst Francois Brisebois upgraded Ovid Therapeutics Inc (NASDAQ:OVID) from Perform to Outperform, establishing a price target of $4.00. The upgrade comes as the stock trades near its ...

This important study offers insights into the function and connectivity patterns of a relatively unknown afferent input from the endopiriform to the CA1 subfield of the ventral hippocampus, suggesting ...

However, there are promising indications that they may play a role in BADs by modulating DA, serotonin or GABA pathways in the reward circuitry. These mechanisms are integral to BADs and may present .